CI Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

69.29B

+5.49%

7.872

+18.56%

67.13B

+2.48%

7.268

+7.83%

71.25B

+6.06%

7.380

+2.5%

Estimates Revision

The market is revising Upward the revenue expectations for The Cigna Group (CI) for FY2025, with the revenue forecasts being adjusted by 2.76% over the past three months. During the same period, the stock price has changed by -6.15%.

Revenue Estimates for FY2025

Revise Upward

+2.76%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-0.16%

In Past 3 Month

Stock Price

Go Down

-6.15%

In Past 3 Month

15 Analyst Rating

Wall Street analysts forecast CI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CI is 337.60 USD with a low forecast of 294.00 USD and a high forecast of 378.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

13 Buy

2 Hold

0 Sell

Strong Buy

Current: 276.110

Low

294.00

Averages

337.60

High

378.00

Current: 276.110

Low

294.00

Averages

337.60

High

378.00

Guggenheim

Buy

maintain

$309 -> $318

2025-12-02

Reason

Guggenheim

Price Target

$309 -> $318

2025-12-02

maintain

Buy

Reason

Guggenheim raised the firm's price target on Cigna to $318 from $309 and keeps a Buy rating on the shares.

BofA

initiated

2025-11-19

Reason

BofA

Price Target

2025-11-19

initiated

Reason

BofA analysts added Cigna to the firm's "US 1 List," which represents a collection of its best investment ideas.

Bernstein

Lance Wilkes

Market Perform

downgrade

$346 -> $294

2025-11-12

Reason

Bernstein

Lance Wilkes

Price Target

$346 -> $294

2025-11-12

downgrade

Market Perform

Reason

Bernstein analyst Lance Wilkes lowered the firm's price target on Cigna to $294 from $346 and keeps a Market Perform rating on the shares following quarterly results. The firm is also adjusting its EPS model to reflect pressure in the PBM margin, with 2026 Evernorth earnings expected down 4% due to Pharmacy Benefit Services subsegment margin declining by an estimated 17%, offset by growth in the specialty segment and Cigna Healthcare.

Goldman Sachs

Scott Fidel

Buy

downgrade

$370 -> $330

2025-11-05

Reason

Goldman Sachs

Scott Fidel

Price Target

$370 -> $330

2025-11-05

downgrade

Buy

Reason

Goldman Sachs analyst Scott Fidel lowered the firm's price target on Cigna to $330 from $370 and keeps a Buy rating on the shares.

Wells Fargo

Equal Weight

downgrade

$354 -> $300

2025-11-05

Reason

Wells Fargo

Price Target

$354 -> $300

2025-11-05

downgrade

Equal Weight

Reason

Wells Fargo lowered the firm's price target on Cigna to $300 from $354 and keeps an Equal Weight rating on the shares. The firm's 2026 / 2027 / 2028 EPS estimates also decrease 10% / 13% / 14% following PBM pressures in 2026. While Wells is sympathetic to arguments that PBM earnings may be overly discounted, low visibility and lack of catalysts keeps the firm on the sidelines.

TD Cowen

Charles Rhyee

Buy

downgrade

$387 -> $333

2025-11-04

Reason

TD Cowen

Charles Rhyee

Price Target

$387 -> $333

2025-11-04

downgrade

Buy

Reason

TD Cowen analyst Charles Rhyee lowered the firm's price target on Cigna to $333 from $387 and keeps a Buy rating on the shares. The firm updated its estimatesfollowing its Q3 results where it introduced its 2026 framework which calls for adj. EPS growth, EHS seeing a slight decline in adj. pre-tax inc. and CI HC growing at the high end of its LT target growth of 7-10%.

Valuation Metrics

The current forward P/E ratio for Cigna Group (CI.N) is 9.05, compared to its 5-year average forward P/E of 10.87. For a more detailed relative valuation and DCF analysis to assess Cigna Group 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

10.87

Current PE

9.05

Overvalued PE

11.97

Undervalued PE

9.76

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

9.05

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

9.88

Undervalued EV/EBITDA

8.22

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.41

Current PS

0.00

Overvalued PS

0.47

Undervalued PS

0.34

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

CI News & Events

Events Timeline

No data

News

8.0

12-15NASDAQ.COM

Significant Options Activity on Monday: CI, RDNT, SOFI

4.5

12-11NASDAQ.COM

Majority of Stocks Bounce Back After Oracle's Sell-Off

3.0

12-11Barron's

Stocks Considered 'Quality' by This Money Manager: Microsoft, Broadcom, Lilly, and More

People Also Watch

Frequently Asked Questions

What is Cigna Group (CI) stock price today?

The current price of CI is 276.11 USD — it has decreased -0.38 % in the last trading day.

What is Cigna Group (CI)'s business?

The Cigna Group is a global health company. The Company has two growth platforms: Evernorth Health Services and Cigna Healthcare. Evernorth Health Services includes its Pharmacy Benefit Services and Specialty and Care Services operating segments, which provide independent and coordinated health solutions and capabilities to enable the healthcare system to work better and help people live richer, healthier lives. Cigna Healthcare includes the U.S. Healthcare and International Health operating segments, which provide comprehensive medical plan services and coordinated solutions to clients and customers. Its Other Operations include corporate-owned life insurance (COLI), the Company's run-off operations and other non-strategic businesses. Specialty and Care Services provides specialty drugs for the treatment of complex and rare diseases, specialty distribution of pharmaceuticals and medical supplies, and clinical programs to help its clients.

What is the price predicton of CI Stock?

What is Cigna Group (CI)'s revenue for the last quarter?

Cigna Group revenue for the last quarter amounts to 69.75B USD, increased 9.50 % YoY.

What is Cigna Group (CI)'s earnings per share (EPS) for the last quarter?

Cigna Group. EPS for the last quarter amounts to 7.02 USD, increased 166.92 % YoY.

What changes have occurred in the market's expectations for Cigna Group (CI)'s fundamentals?

How many employees does Cigna Group (CI). have?

Cigna Group (CI) has 73500 emplpoyees as of December 16 2025.

What is Cigna Group (CI) market cap?

Today CI has the market capitalization of 74.01B USD.